CDNA CareDx Forecast, Technical & Fundamental Analysis
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers... Show more
CDNA is expected to report earnings to fall 31.76% to 23 cents per share on July 30
Q2'26
Est.
$0.23
Q1'26
Beat
by $0.40
Q4'25
Beat
by $0.11
Q3'25
Beat
by $0.36
Q2'25
Beat
by $0.20
The last earnings report on April 28 showed earnings per share of 34 cents, beating the estimate of -5 cents. With 228.68K shares outstanding, the current market capitalization sits at 1.92B.
A.I. Advisor
published General Information
General Information
a molecular diagnostics company which develops, markets and delivers diagnostic surveillance solutions for organ transplant recipients
A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with BLFS. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then BLFS could also see price increases.
The Moving Average Convergence Divergence (MACD) for CDNA turned positive on July 16, 2026. Looking at past instances where CDNA's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 15, 2026. You may want to consider a long position or call options on CDNA as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where CDNA advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 174 cases where CDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for CDNA moved out of overbought territory on July 24, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CDNA broke above its upper Bollinger Band on July 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CDNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.116) is normal, around the industry mean (13.307). P/E Ratio (14.887) is within average values for comparable stocks, (150.960). CDNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.685). CDNA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.008). P/S Ratio (4.744) is also within normal values, averaging (8.160).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 92, placing this stock worse than average.
